Follow us on Twitter
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS
|| List of recent Leukemia-related patents
|Tyrosine, serine and threonine phosphorylation sites|
The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including aqua peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.. .
|Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging|
The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Natural and synthetic compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
|Cyclin a1-targeted t-cell immunotherapy for cancer|
Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
|Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells|
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (aml) and b-cell acute lymphoid leukemia (b-all). The invention also relates to at least one chimeric antigen receptor (car) specific to cd123, vectors comprising the same, and recombinant t cells comprising the cd123 car.
|Treatment of hematologic malignancies with an anti-cxcr4 antibody|
The present disclosure provides human monoclonal antibodies that bind specifically to cxcr4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a cxcr4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-cxcr4 antibody of the disclosure.
|Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia|
The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of b-precursor acute lymphoblastic leukemia (all) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.. .
|Treatment of cancer with dihydropyrazino-pyrazines|
Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a dihydropyrazino-pyrazine compound to a patient having chronic lymphocytic leukemia.. .
|Achillea fragrantissima extract, method for preparing achillea fragrantissima extract and method for treating chronic myeloid leukemia|
An achillea fragrantissima extract for treating chronic myeloid leukemia cells is made by the following steps: washing a mass of achillea fragrantissima leaves and powdering the dried leaves. The leaves are dried over seven days and a kilo of the powder is extracted three times with methanol.
|Compositions and methods for treatment of cytomegalovirus|
The present disclosure provides compositions and methods useful for treating hcmv infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (vlps) which comprise one or more moloney murine leukemia virus (mmlv) core proteins and include one or more hcmv epitopes, such as, for example, from hcmv envelope glycoproteins gb and/or gh and/or tegument protein pp65.
|Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies|
Compositions including an antibody specific for cd44 are provided. These antibodies specifically bind to hematologic malignant cells.
|Methods of treating and preventing leukemia and other cancers of the blood and bone|
The present invention relates to preventing and treating leukemia and other cancers of the blood and bone, as well as disorders of the blood, by inhibiting gut-derived serotonin. The inhibition of the gut-derived serotonin is accomplished by inhibiting tph1, an enzyme responsible for the production of gut-derived serotonin.
|Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias|
The present invention relates to a method of treating a warm-blooded animal, especially a human, having mixed lineage leukemia (mll rearranged all) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially pkc412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of mll rearranged all; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of mll rearranged all.. .
The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives.
|Zap-70 detection in chronic lymphocytic leukemia|
Detection of zap-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (cll). The invention provides methods for diagnosing cll in a subject, as well as methods for clearly distinguishing cll patients with aggressive form of the disease.
|Compositions and methods for cancer and cancer stem cell detection and elimination|
In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded rna-specific adenosine deaminases, or adar, enzymes.
|Combination cancer therapy with an hsp90 inhibitor and an antimetabolite|
The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (i) 40 or (ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives.. .
|T cell receptor-like antibodies specific for a wti peptide presented by hla-a2|
The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
|Pgam1 inhibitors and methods related thereto|
In certain embodiments, the disclosure relates to methods of treating or preventing a pgam1 mediated condition such as cancer or tumor growth comprising administering an effective amount of pgam1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof..
|Use of carbamide peroxide injection in preparation of virus inactivation medicaments for treating diseases|
The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, aids and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen (1o2) under the effect of a method using laser, x-ray, ultrasound and medicament, etc., while in condition of using carbamide peroxide injection series.
|N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia|
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide, that inhibits the t315i mutation in bcr-abl tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide, that inhibits the t315i mutation in bcr-abl tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent..
|Chimeric antigen receptor specific for folate receptor beta|
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (aml). The invention also relates to at least one chimeric antigen receptor (car) specific to folate receptor beta (frβ), vectors comprising the same, and recombinant t cells comprising the frβ car.
|Notch agonists for the treatment of cancer|
The present invention is directed to methods of treating and preventing acute myeloid leukemia and acute myeloid leukemia relapse disease in a subject that involve administering a notch receptor agonist.. .
|Methods, pharmaceutical compositions and kits for use in the treatment of adult t-cell leukemia/lymphoma|
The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of adult t-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of adult t-cell leukemia/lymphoma..
|Indirubin derivatives, and uses thereof|
Indirubin is the major active anti-tumor component of a traditional chinese herbal medicine used for treatment of chronic myelogenous leukemia (cml). Indirubin derivatives (irds) potently reduce the viabilities of various cancer cells and affect kinase activities.
|Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof|
The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine class compounds and methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of mll1 and mll2 or menin)..
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.